New data show breakthrough microRNA-targeted therapy holds promise as new treatment for hepatitis C
Thursday, December 3, 2009 - 22:21
in Health & Medicine
Hoersholm, Denmark/San Diego, California, December 3, 2009 — A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).
